Final Program

208 MONDAY • MAY 16
Objectives
At the conclusion of this session, the participant will be able to:
• describe findings from innovative educational research programs;
• understand and describe strategies for effective transfer of sleep and
circadian scientific knowledge;
• describe communication goals and methods of implementation in health
care and communities settings.
This session will present data-based findings and progress from an NHLBI
initiative that aims to develop educational strategies for the dissemination of
sleep and circadian biology based health information to health care providers
and minority communities. The presentations will focus on improving sleep
apnea health literacy through community-based engagement, improving
sleep/circadian rhythms and the detection of sleep disorders in the inpatient
setting, and enhanced sleep/circadian medical education via telemedicine for
residents and primary care physicians.
Chairing M. Twery, PhD, Bethesda, MD
J. Girardin, PhD, New York, NY
12:15 Tailored Sleep Health Education: A Community-Engaged
Approach
J. Girardin, PhD, New York, NY
12:35 Tackling the Elephant in the Room: Educating Hospital Staff
About Sleep Medicine
A. Vineet, MD,Chicago, IL
12:55 Use of Telemedicine to Promote Sleep Medicine Education in
Health Care
I. Rosen, MD, MS, Philadelphia, PA
L18
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
HOW THE NHLBI K12 PROGRAM IS ADVANCING
OUR KNOWLEDGE IN THE OMICS OF LUNG
DISEASE
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 2001/2003 (West Building, Level 2)
Target Audience
Those interested in the application of omics technologies to the diagnosis and
therapy of all lung diseases; those interested in training young investigators in
lung research, providers of lung health; those with clinical or research
responsibility.
Objectives
At the conclusion of this session, the participant will be able to:
• gain new strategies for training young investigators;
• learn new ways to apply omics to questions about lung disease;
• gain new strategies for diagnosing, treating and predicting the course of
specific lung diseases.
The K12 in omics of lung diseases is an NHLBI sponsored career development
program with the objective to develop an interdisciplinary program that will
educate young pulmonary investigators in methods of integrative “omics”
technologies including genomics, proteomics, metabolomics, bioinformatics,
computational modeling and system biology. Participants in this session will
learn about the structure and organization of the different programs and how the
elements of each program interconnect to create an integrated and
multidisciplinary learning experience
Chairing: C.M. Doerschuk, MD, Chapel Hill, NC
S. Colombini-Hatch, MD, Bethesda, MD
12:15 Computational Skill Building
J.A. Whitsett, MD, Cincinnati, OH
12:35 High Through Proteomics
M. Rabinovitch, MD, Stanford, CA
12:55 Discussion
S. Colombini-Hatch, MD, Bethesda, MD
C.M. Doerschuk, MD, Chapel Hill, NC
L19
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
GENETIC BASIS OF IDIOPATHIC PULMONARY
FIBROSIS
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Target Audience
Health care providers, researchers and patients.
Room 2020/2022 (West Building, Level 2)
Objectives
At the conclusion of this session, the participant will be able to:
• explain our current understanding of IPF pathogenesis;
• refer patients for future studies in IPF;
• plan gene-to-function studies to fill knowledge gaps in IPF and identify novel
therapeutic targets.
There have been substantial advances in our understanding of the pathogenesis of
idiopathic pulmonary fibrosis (IPF) through several genome-wide association studies
(GWAS) of and linkage studies of families that have two or more family members with this
disease. GWAS have identified many candidate genes that may contribute to disease
risk. Linkage studies of families have identified causal mutations of surfactant protein or
telomerase complex genes that are also found in certain sporadic cases of IPF. Thus,
rather than existing as distinct syndromes, sporadic and familial cases of IPF probably
reflect a continuum of genetic risk. The presenters will 1) present the latest research
results, 2) discuss a novel hypothesis of IPF pathogenesis based on GWAS studies, 3)
describe how cutting-edge bioinformatic and next-generation sequencing techniques
could allow an integrated approach to defining IPF pathogenesis and 4) how to apply
these advances to achieve personalized medicine in IPF.
Chairing: C.K. Garcia, MD, PhD, Dallas, TX
J. Eu, MD, Bethesda, MD
12:15 Mechanisms of Pulmonary Fibrosis
T.S. Blackwell, MD, Nashville, TN
12:30 Genetics of Pulmonary Fibrosis: New Genes, New Mutations,
Same Pathway
C.K. Garcia, MD, PhD, Dallas, TX
ATS 2016 • San Francisco